EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.42 (4.24%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $10.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
EYPT 10.33 +0.42(4.24%)
Will EYPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EYPT
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
Other News for EYPT
EyePoint Pharmaceuticals Earns ‘Outperform’ Rating on Promising Duravyu Data and Strategic FDA Alignment
TD Cowen Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Results
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
EyePoint announces developments on DURAVYU